Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 10:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 245 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: N-acetylcysteine (NAC) Clear all
Recruiting Phase 2 Interventional

Efficacy of Rifaximin With NAC in IBS-D

NCT06727422
View directory record Official record
Conditions
IBS (Irritable Bowel Syndrome), IBS-D (Diarrhea-predominant)
Interventions
rifaximin 66mg + N-acetylcysteine 560mg three times daily, RNIB21 containing rifaximin 132mg + N-acetylcysteine 560mg three times daily, Placebo
Drug
Lead sponsor
Mark Pimentel, MD
Other
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 14, 2026, 10:53 AM EDT
Completed Phase 2 Interventional Results available

NAC for Treating Comorbid PTSD and SUD

NCT02911285
View directory record Official record
Conditions
Posttraumatic Stress Disorder (PTSD), Alcohol Use Disorder (AUD), Substance Use Disorder (SUD)
Interventions
N-acetylcysteine, Placebo, Cognitive behavioral therapy
Drug · Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 14, 2026, 10:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of HPN-07 and HPN-07 Plus NAC

NCT02259595
View directory record Official record
Conditions
Hearing Loss, Sensorineural Hearing Loss, Noise-Induced Hearing Loss
Interventions
HPN-07, NAC, Placebo
Drug
Lead sponsor
Otologic Pharmaceutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated May 1, 2015 · Synced Oct 14, 2026, 10:53 AM EDT
Completed Phase 2 Interventional Results available

An Open-Label Study of N-Acetyl Cysteine in Children With Autism

NCT00676195
View directory record Official record
Conditions
Autistic Disorder
Interventions
N-Acetyl Cysteine
Drug
Lead sponsor
Stanford University
Other
Eligibility
3 Years to 12 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 14, 2026, 10:53 AM EDT
Completed Phase 1 Interventional

Pilot Study of Anti-oxidant Supplementation With N-Acetyl Cysteine in Stage 0/I Breast Cancer

NCT01878695
View directory record Official record
Conditions
Stage 0/1 Breast Cancer, Post Biopsy, Pre-surgery
Interventions
IV/oral n-acetylcysteine
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 2, 2025 · Synced Oct 14, 2026, 10:53 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

NAC for Attenuation of COVID-19 Symptomatology

NCT05074121
View directory record Official record
Conditions
Covid19, COVID-19 Pneumonia, COVID-19 Respiratory Infection, COVID-19 Lower Respiratory Infection, SARS-CoV2 Infection, SARS-CoV-2 Acute Respiratory Disease, SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere, Oxidative Stress
Interventions
N-acetylcysteine, Placebo
Drug · Other
Lead sponsor
Cambridge Health Alliance
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Everett, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 7, 2023 · Synced Oct 14, 2026, 10:53 AM EDT
Completed Phase 1 Interventional

Nutrition, Neuromuscular Electrical Stimulation (NMES) and Secondary Progressive Multiple Sclerosis (SPMS)

NCT01381354
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Progressive exercise, Neuromuscular electrical stimulation delivered using the electrical therapy device EMPI 300 PV, Modified paleolithic diet, Omega 3 fatty acids, Full Spectrum vitamin, Essential - hydroxytyrosol, Maltodextrin fiber supplement, Mineral boost (magnesium), Niacinamide, Methyl B12, Taurine, creatine, thiamine, riboflavin, N acetylcysteine, alpha lipoic acid, L acetyl carnitine, methyl folate, coenzyme Q, meditation, self massage, learning, Coconut oil
Other · Device · Dietary Supplement + 1 more
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Oct 14, 2026, 10:53 AM EDT
Completed Phase 3 Interventional Results available

Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in Patients With IPF

NCT00650091
View directory record Official record
Conditions
Pulmonary Fibrosis
Interventions
N-acetylcysteine (NAC), Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
35 Years to 85 Years
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
26
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Oct 14, 2026, 10:53 AM EDT
Completed Phase 2 Interventional Results available

N-Acetylcysteine in Neonatal Congenital Heart Surgery (INACT Study)

NCT00374088
View directory record Official record
Conditions
Transposition of Great Vessels, Congenital Heart Disease
Interventions
N-acetylcysteine, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
Up to 3 Months
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 19, 2012 · Synced Oct 14, 2026, 10:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Energetics and Function in Older Humans

NCT02348762
View directory record Official record
Conditions
Aging, Erythrocyte Glutathione Deficiency, Muscle Weakness
Interventions
Cysteine (as n-acetylcysteine) and Glycine
Dietary Supplement
Lead sponsor
Baylor College of Medicine
Other
Eligibility
21 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2022 · Synced Oct 14, 2026, 10:53 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety and Efficacy of Mucinex and IR Guaifenesin the Treatment of Symptoms of Acute Upper Respiratory Tract Infections

NCT01537081
View directory record Official record
Conditions
Acute Upper Respiratory Tract Infection
Interventions
Mucinex, Immediate-release Guaifenesin, Placebo
Drug
Lead sponsor
Reckitt Benckiser LLC
Industry
Eligibility
12 Years and older
Enrollment
2,810 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
43
States / cities
Hoover, Alabama • Bell Gardens, California • Harbor City, California + 38 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2013 · Synced Oct 14, 2026, 10:53 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease

NCT04419025
View directory record Official record
Conditions
COVID, Sars-CoV2, SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere, Oxidative Stress
Interventions
N-acetylcysteine
Drug
Lead sponsor
Cambridge Health Alliance
Other
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
4
States / cities
Cambridge, Massachusetts • Everett, Massachusetts • Somerville, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 28, 2021 · Synced Oct 14, 2026, 10:53 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Pilot Study of Losartan and N-acetylcysteine as Inhibitors of Muscle Oxidative Stress in Elderly

NCT01384591
View directory record Official record
Conditions
Aging
Interventions
N-acetylcysteine, Losartan, Placebo losartan, Placebo N-acetylcysteine
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
60 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Oct 14, 2026, 10:53 AM EDT
Recruiting Phase 2 Interventional

Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy

NCT04440280
View directory record Official record
Conditions
Fuchs Endothelial Corneal Dystrophy
Interventions
N-acetyl cysteine (NAC) 10% solution, N-acetyl cysteine (NAC) 20% solution, Visine Dry Eye Relief eye drops
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
21 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 14, 2026, 10:53 AM EDT
Not yet recruiting Phase 2 Interventional

Use of N-Acetylcysteine in the Treatment of Repetitive and Self-Injurious Behaviors in Cornelia de Lange Syndrome

NCT04381897
View directory record Official record
Conditions
Cornelia de Lange Syndrome
Interventions
N-acetyl cysteine, Placebo
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
13 Years to 35 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 14, 2026, 10:53 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

NAC-003 P.L.U.S. Program (Progress Through Learning Understanding & Support)

NCT01370954
View directory record Official record
Conditions
Early Memory Loss, Mild Cognitive Impairment, Alzheimer's Disease, Vascular Dementia
Interventions
CerefolinNAC®
Other
Lead sponsor
Pamlab, Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
204 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Hickory, North Carolina
Source: ClinicalTrials.gov public record
Updated May 9, 2013 · Synced Oct 14, 2026, 10:53 AM EDT
Terminated Phase 2 Interventional Results available

N-Acetylcysteine in Adjunct to DBT for the Treatment of Self-Injurious Behavior in BPD

NCT00539188
View directory record Official record
Conditions
Borderline Personality Disorder, Self-Injurious Behavior
Interventions
N-Acetylcysteine, placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 15, 2020 · Synced Oct 14, 2026, 10:53 AM EDT
Withdrawn Early Phase 1 Interventional

The Role of Glutathione Deficiency and MSIDS Variables in Long COVID-19

NCT05371288
View directory record Official record
Conditions
COVID-19
Interventions
NAC (N-acetyl cysteine), Alpha lipoic acid (ALA), liposomal glutathione (GSH)
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Oct 14, 2026, 10:53 AM EDT
Completed Phase 2 Interventional Results available

N-Acetylcysteine for Adolescent Alcohol Use Disorder

NCT03707951
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
N-acetylcysteine, Placebo oral capsule
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
13 Years to 25 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Oct 14, 2026, 10:53 AM EDT
Terminated Phase 3 Interventional Results available

Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD

NCT02411084
View directory record Official record
Conditions
Graft vs Host Disease
Interventions
Begelomab, Conventional Second-line Treatment
Biological
Lead sponsor
Adienne SA
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
10
States / cities
Duarte, California • Westwood, Kansas • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2020 · Synced Oct 14, 2026, 10:53 AM EDT
Completed Phase 2 Interventional Results available

Imaging GABAergic/Glutamatergic Drugs in Bipolar Alcoholics Alcoholics

NCT03220776
View directory record Official record
Conditions
Alcohol Use Disorder, Bipolar Disorder
Interventions
N-Acetylcysteine, Gabapentin, Placebo Oral Tablet
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Oct 14, 2026, 10:53 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Antioxidant Therapy With N-acetylcysteine for Learning and Motor Behavior in Children With Neurofibromatosis Type 1

NCT04481035
View directory record Official record
Conditions
Neurofibromatosis 1
Interventions
N-acetylcysteine (NAC), Placebo
Drug · Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
8 Years to 16 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 14, 2026, 10:53 AM EDT
Recruiting Phase 2Phase 3 Interventional

BabySTrong II taVNS Feeding Trial

NCT07049952
View directory record Official record
Conditions
Feeding Delays, Neonates and Term Infants
Interventions
taVNS, NAC and taVNS, inactive taVNS, sterile water and inactive taVNS
Device · Combination Product
Lead sponsor
Medical University of South Carolina
Other
Eligibility
39 Weeks to 54 Weeks
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 14, 2026, 10:53 AM EDT
Completed Phase 2 Interventional

Study of Expectorant Activity of Oral N-acetylcystein (NAC) in Patients With Stable Chronic Bronchitis

NCT00205647
View directory record Official record
Conditions
Chronic Bronchitis
Interventions
Oral N-acetycystein (NAC)
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years to 75 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 14, 2026, 10:53 AM EDT